POGGESI, ITALO
 Distribuzione geografica
Continente #
EU - Europa 779
NA - Nord America 439
AS - Asia 228
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.451
Nazione #
NL - Olanda 473
US - Stati Uniti d'America 435
CN - Cina 192
IE - Irlanda 140
FI - Finlandia 36
IT - Italia 34
SG - Singapore 33
DE - Germania 32
UA - Ucraina 31
SE - Svezia 13
GB - Regno Unito 7
CA - Canada 4
AU - Australia 3
BE - Belgio 3
PL - Polonia 3
RU - Federazione Russa 3
PT - Portogallo 2
CZ - Repubblica Ceca 1
EU - Europa 1
FR - Francia 1
KG - Kirghizistan 1
KR - Corea 1
NZ - Nuova Zelanda 1
TR - Turchia 1
Totale 1.451
Città #
Dublin 140
Chandler 100
Jacksonville 49
Nanjing 45
Beijing 29
Singapore 29
Boardman 23
Ashburn 21
Princeton 20
Helsinki 19
Wilmington 19
Hebei 17
Lawrence 17
Nanchang 17
Medford 16
Dearborn 15
Jiaxing 15
Shanghai 15
Changsha 14
Ann Arbor 12
Shenyang 12
Tianjin 8
Hangzhou 7
Los Angeles 6
Milan 6
Cagliari 4
Chicago 4
Dallas 4
Houston 4
Pavia 4
Piscataway 4
Seattle 4
Toronto 4
Woodbridge 4
Brussels 3
Krakow 3
Saint Petersburg 3
Zhengzhou 3
Coimbra 2
Garching 2
Norwalk 2
Perth 2
San Francisco 2
Taizhou 2
Auckland 1
Augusta 1
Bishkek 1
Brno 1
Carate Brianza 1
Changchun 1
Des Moines 1
Dolo 1
Fairfield 1
Henderson 1
Kunming 1
Lurate Caccivio 1
Lynnwood 1
Melbourne 1
Ningbo 1
Oklahoma City 1
Olgiate Olona 1
Origgio 1
Paris 1
Rivarolo Canavese 1
Seocho-gu 1
Seregno 1
Sunnyvale 1
Vaiano Cremasco 1
Verona 1
Weil am Rhein 1
Totale 757
Nome #
Steady-state equivalence of drug- and biomarker driven models in tumor growth experiments 538
Tumor-growth inhibition in preclinical animal studies: steady-state analysis of biomarker-driven models 91
Biomarker-driven models of tumor growth inhibition in preclinical animal studies 80
Tumor growth modelling for drug development 73
Integration of response, tolerability and dropout in flexible-dose trials: a case study in depression 71
Predictive assessments of pharmacokinetic alterations in subjects with renal disease 62
Method to evaluate the systemic exposure in toxicological and pharmacological studies 56
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies 56
Use of Physiology-Based Elements to Predict the Pharmacokineticsof New Drugs 52
Mathematical modeling of efficacy and safety for anticancer drugs clinical development 51
Current mathematical models for cancer drug discovery 48
Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs 46
Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis 46
Pharmacokinetic-Pharmacodynamic Modeling in Drug Development with Special Reference to Oncology 44
A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension 43
Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity 35
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib 34
Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis 31
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial 27
Totale 1.484
Categoria #
all - tutte 4.917
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.917


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202062 0 0 0 0 0 12 5 10 1 13 21 0
2020/202168 7 5 2 7 1 8 0 13 4 10 9 2
2021/2022562 1 1 4 0 1 2 0 18 1 0 16 518
2022/2023340 40 27 10 12 25 25 1 19 161 3 7 10
2023/2024129 32 20 0 12 8 17 9 15 2 4 6 4
2024/202567 8 24 6 4 23 2 0 0 0 0 0 0
Totale 1.484